Ceftacrit-TZ Injection is a broad-spectrum antibacterial combination of Ceftazidime, a third-generation cephalosporin, and Tazobactam, a beta-lactamase inhibitor. This formulation is designed to effectively treat moderate to severe bacterial infections, including those caused by beta-lactamase-producing organisms.
Ceftazidime works by inhibiting bacterial cell wall synthesis, while Tazobactam enhances its activity by preventing enzymatic degradation. Together, they provide extended antibacterial coverage, particularly against gram-negative pathogens, making Ceftacrit-TZ suitable for challenging and resistant infections.
It is commonly indicated for the treatment of respiratory tract infections, urinary tract infections, intra-abdominal infections, skin and soft tissue infections, septicemia, and hospital-acquired infections. The injection is intended for IM/IV use only and is supplied as a single-use vial, ensuring accurate dosing and safety in clinical settings.
Manufactured under stringent quality standards, Ceftacrit-TZ Injection offers high purity, stability, and consistent therapeutic performance, making it a reliable choice for hospitals and healthcare professionals.
Ceftacrit-TZ Injection supports effective infection control and improved patient outcomes through dependable antibiotic therapy.
This information is for registered medical practitioner only. Anyone other than medical practitioner should consult medical practitioner before using this product.